TCGA-CR-7392-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- IL6_JAK_STAT3_SIGNALING+0.480
- ALLOGRAFT_REJECTION+0.440
- ANGIOGENESIS+0.400
- COMPLEMENT+0.390
- INFLAMMATORY_RESPONSE+0.390
- KRAS_SIGNALING_UP+0.390
- UV_RESPONSE_DN+0.370
Top 10 suppressed
- MYC_TARGETS_V1-0.610
- OXIDATIVE_PHOSPHORYLATION-0.580
- E2F_TARGETS-0.570
- MYC_TARGETS_V2-0.560
- G2M_CHECKPOINT-0.480
- DNA_REPAIR-0.370
- MTORC1_SIGNALING-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- FATTY_ACID_METABOLISM-0.260
- CHOLESTEROL_HOMEOSTASIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.937 |
| 2 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.925 |
| 3 | 1b192a49-01cb-4459-a7a7-fdebe428f386 | — | — | 0.916 |
| 4 | 653522fe-3289-4e1f-9373-c81f923893a3 | — | — | 0.910 |
| 5 | TCGA-CN-5373-01A-01R-1436-07 | — | — | 0.905 |
| 6 | TCGA-CR-7394-01A-11R-2016-07 | — | — | 0.904 |
| 7 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.901 |
| 8 | SRR5088925 | — | — | 0.901 |
| 9 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.900 |
| 10 | be66e85c-d70d-4073-af6a-bcee51ef3240 | — | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |